This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Eli Lilly to sell dog drug assets to Virbac to secure approval for purchase of Novartis animal health unit

( October 29, 2014, 18:43 GMT | Official Statement) -- MLex Summary: Pharmaceutical companies Eli Lilly and Novartis have agreed to divest certain assets related to two major parasiticides for dogs in order to secure approval from the US Federal Trade Commission for their deal, according to a Eli Lilly regulatory filing on Wednesday. Eli Lilly is seeking to acquire the animal-health unit of Novartis for $5.4 billion. The companies have entered into an agreement to sell these assets to Virbac Corporation, subject to approval from the FTC. The transaction is expected to close by the end of the first quarter of 2015.Extract....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login